Health and Healthcare
Mylan Falls Short on Revenues, Hints at Acquisition to Come
Published:
Mylan Inc. (NASDAQ: MYL) reported first-quarter 2014 results before markets opened Thursday. The pharmaceutical company posted adjusted diluted earnings per share (EPS) of $0.66 on revenues of $1.72 billion. In the same period a year ago, the company reported adjusted EPS of $0.62 on revenues of $1.63 billion. First-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.64 and $1.78 billion in revenues.
Third party net sales from Mylan’s Generics segment increased 7.1% year-on-year to $1.51 billion. In North America they increased 6.9% to $782.2 million, and in Europe by 2.1% to $355.9 million. Third party net sales from the Rest of World grew 12.9% to $370.2 million. But Mylan’s Specialty segment reported third party net sales down 8.0% to $211.6 million.
The company’s CEO said:
Mylan’s performance during the first quarter slightly exceeded our expectations and marked a great start to what we believe will be another good year. Our operations in India drove strong top-line growth as a result of increased sales from our antiretroviral franchise. Additionally, the diversity and strength of our product portfolio in North America demonstrated our ability to continue to leverage our operating platform. We remain confident in our outlook for the rest of 2014, and we are reaffirming our full year guidance, including the adjusted diluted EPS guidance range of $3.25 to $3.60. With respect to mergers and acquisitions, as we have stated in the past, we continue to be very active in exploring a number of potential transactions and we remain confident that we will be in a position to execute on a substantial transaction by year end.
SEE ALSO: Five Top Health Care Names From RBC to Buy Now
The consensus analysts’ estimate for the full year so far calls for EPS of $3.44 on revenues of $7.91 billion. For the current quarter, analysts estimate EPS at $0.86 on $1.97 billion in revenue.
Earlier this week, Mylan’s second bid for Swedish drug maker Meda was rejected due to opposition of the latter’s largest shareholder.
Mylan shares were inactive in premarket trading Thursday, having closed Wednesday down fractionally at $50.78, in a 52-week range of $27.77 to $57.52. Thomson Reuters had a consensus analyst price target of around $61.00 before this report.
SEE ALSO: Companies With the Best (and Worst) Reputations
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.